Please assess the completion status of the following clinical trial:

Trial Title: Are the Cardiac Benefits of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients should meet the following inclusion criteria:~* Ambulatory patients age 18-85 years~* Diagnosis of Heart failure (NYHA II to III)~* LVEF\<50% on echocardiography or CMRI in the previous 6 months~* Have stable symptoms and therapy for HF within the last 3 months.~Exclusion Criteria:~* Pregnant or lactating women.~* Any history of diabetes by medical history or by any of the established criteria by the American Diabetes Association. It also includes patients with history of diabetes in remission.~* ACS or cardiac surgery within the last 3 months.~* Cancer or any other life-threatening condition.~* Pancreatitis.~* Glomerular Filtration Rate \< 45 ml/Kg/min.~* Use of continuous parental inotropic agents.~* Systolic BP \< 90 mm Hg.~* Psychiatric disease incompatible with being in study.~* Any contraindication to MRI procedures.~* Any other medical or physical condition considered to be inappropriate by a study physician.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: EXPERIMENTAL): 10mg once a day
- Placebos (Type: PLACEBO_COMPARATOR): placebo once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).